2. Home
  3. Conference Highlights
  4. ASCO 2017
  5. ASCO 2017 Prostate Cancer

ASCO 2017 Prostate Cancer

ASCO 2017: Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?

Chicago, IL (UroToday.com) Dr. Alberto Briganti gave an interesting discussion on the presentation and biologic characteristics of prostate cancer (PC) in older patients. The presentation objectives were to assess candidates for early diagnosis and local treatment, assess determinants of pathological and long term outcomes, and evaluate outcomes of men treated with curative intent.

ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom

Chicago, IL (UroToday.com) Dr. Nicholas James elegantly presented some thoughts and conclusions from the ongoing STAMPEDE trial. This trial examines addition of further treatments to standard of care in prostate cancer (PC). It recruits men from 4 groups starting long term androgen deprivation therapy (ADT):

ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer

Chicago, IL (UroToday.com) Dr. Alicia Morgans from Vanderbilt University concluded the “Disparities in Screening and Treatment of Prostate Cancer for the Older Patient” session at the 2017 ASCO meeting with an excellent talk regarding the physical and cognitive effects of systemic therapy in older men with prostate cancer.

ASCO 2017: Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer

Chicago, IL (UroToday.com) Dr. William Dale from the City of Hope in Los Angeles provided an important and interesting discussion from a geriatrician’s perspective regarding key aspects of interdisciplinary and integrated treatment planning for effectively treating older patients with prostate cancer at the ASCO 2017 “Disparities in Screening and Treatment of Prostate Cancer for the Older Patient” session.

ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease

Chicago, IL (UroToday.com) Dr. Juergen Gschwend, from Munich, Germany, provided an excellent summary of the advances in molecular imaging, specifically PSMA PET scan, in prostate cancer (PCa) management. As Germany has been a leader in this technology, his experience with the technology provided an important context for the discussion.

ASCO 2017: Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP)

Chicago, IL (UroToday.com) There has been a paradigm shift over the last several years regarding treating high risk patients up front with multimodal therapy with the hope of long-term survival durability. Along this line of thinking, Dr. Emmanuel Antonarakis and colleagues presented results of their neoadjuvant randomized trial of degarelix with or without cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer undergoing radical prostatectomy at the prostate cancer poster session at the 2017 ASCO annual meeting.

ASCO 2017: Targeting the AR: Biomarkers and Novel Therapeutic Approaches

Chicago, IL (UroToday.com) Dr. Terence Friedlander focused on targeting the androgen receptor (AR), with an emphasis on biomarkers and novel therapeutic approaches. In the setting of metastatic prostate cancer (PCa), androgen deprivation therapy (ADT) remains the standard of care.
Page 1 of 13